These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31512530)

  • 1. Proteomics advances for precision therapy in ovarian cancer.
    Labrie M; Kendsersky ND; Ma H; Campbell L; Eng J; Chin K; Mills GB
    Expert Rev Proteomics; 2019 Oct; 16(10):841-850. PubMed ID: 31512530
    [No Abstract]   [Full Text] [Related]  

  • 2. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.
    Wang ZC; Birkbak NJ; Culhane AC; Drapkin R; Fatima A; Tian R; Schwede M; Alsop K; Daniels KE; Piao H; Liu J; Etemadmoghadam D; Miron A; Salvesen HB; Mitchell G; DeFazio A; Quackenbush J; Berkowitz RS; Iglehart JD; Bowtell DD; ; Matulonis UA
    Clin Cancer Res; 2012 Oct; 18(20):5806-15. PubMed ID: 22912389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
    George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
    Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing.
    Cybulska P; Stewart JM; Sayad A; Virtanen C; Shaw PA; Clarke B; Stickle N; Bernardini MQ; Neel BG
    Am J Pathol; 2018 May; 188(5):1120-1131. PubMed ID: 29458007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes.
    Govindarajan M; Ignatchenko V; Ailles L; Kislinger T
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma.
    Tessier-Cloutier B; Cochrane DR; Karnezis AN; Colborne S; Magrill J; Talhouk A; Zhang J; Leung S; Hughes CS; Piskorz A; Cheng AS; Greening K; du Bois A; Pfisterer J; Soslow RA; Kommoss S; Brenton JD; Morin GB; Gilks CB; Huntsman DG; Kommoss F
    Hum Pathol; 2020 Jul; 101():40-52. PubMed ID: 32360491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma.
    Tamura N; Shaikh N; Muliaditan D; Soliman TN; McGuinness JR; Maniati E; Moralli D; Durin MA; Green CM; Balkwill FR; Wang J; Curtius K; McClelland SE
    Cancer Res; 2020 Nov; 80(22):4946-4959. PubMed ID: 32998996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of Proteomics in Ovarian Cancer: Dawn of a New Era.
    Ghose A; Gullapalli SVN; Chohan N; Bolina A; Moschetta M; Rassy E; Boussios S
    Proteomes; 2022 May; 10(2):. PubMed ID: 35645374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
    Holý P; Hlaváč V; Šeborová K; Šůsová S; Tesařová T; Rob L; Hruda M; Bouda J; Bartáková A; Mrhalová M; Kopečková K; Al Obeed Allah M; Špaček J; Sedláková I; Souček P; Václavíková R
    Int J Cancer; 2024 Jul; 155(1):104-116. PubMed ID: 38447012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.
    Hu Y; Pan J; Shah P; Ao M; Thomas SN; Liu Y; Chen L; Schnaubelt M; Clark DJ; Rodriguez H; Boja ES; Hiltke T; Kinsinger CR; Rodland KD; Li QK; Qian J; Zhang Z; Chan DW; Zhang H;
    Cell Rep; 2020 Oct; 33(3):108276. PubMed ID: 33086064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer.
    Zhang H; Liu T; Zhang Z; Payne SH; Zhang B; McDermott JE; Zhou JY; Petyuk VA; Chen L; Ray D; Sun S; Yang F; Chen L; Wang J; Shah P; Cha SW; Aiyetan P; Woo S; Tian Y; Gritsenko MA; Clauss TR; Choi C; Monroe ME; Thomas S; Nie S; Wu C; Moore RJ; Yu KH; Tabb DL; Fenyö D; Bafna V; Wang Y; Rodriguez H; Boja ES; Hiltke T; Rivers RC; Sokoll L; Zhu H; Shih IM; Cope L; Pandey A; Zhang B; Snyder MP; Levine DA; Smith RD; Chan DW; Rodland KD;
    Cell; 2016 Jul; 166(3):755-765. PubMed ID: 27372738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
    Lapke N; Chen CH; Chang TC; Chao A; Lu YJ; Lai CH; Tan KT; Chen HC; Lu HY; Chen SJ
    BMC Cancer; 2021 May; 21(1):499. PubMed ID: 33947352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genomic trajectory of ovarian high-grade serous carcinoma can be observed in STIC lesions.
    Cheng Z; Ennis DP; Lu B; Mirza HB; Sokota C; Kaur B; Singh N; Le Saux O; Russo G; Giannone G; Tookman LA; Krell J; Barnes C; McDermott J; McNeish IA
    J Pathol; 2024 Sep; 264(1):42-54. PubMed ID: 38956451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management.
    Bradbury M; Borràs E; Vilar M; Castellví J; Sánchez-Iglesias JL; Pérez-Benavente A; Gil-Moreno A; Santamaria A; Sabidó E
    J Transl Med; 2022 Dec; 20(1):611. PubMed ID: 36544142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
    Bashashati A; Ha G; Tone A; Ding J; Prentice LM; Roth A; Rosner J; Shumansky K; Kalloger S; Senz J; Yang W; McConechy M; Melnyk N; Anglesio M; Luk MT; Tse K; Zeng T; Moore R; Zhao Y; Marra MA; Gilks B; Yip S; Huntsman DG; McAlpine JN; Shah SP
    J Pathol; 2013 Sep; 231(1):21-34. PubMed ID: 23780408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive molecular portraits of human breast tumours.
    Cancer Genome Atlas Network
    Nature; 2012 Oct; 490(7418):61-70. PubMed ID: 23000897
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Valle BL; Rodriguez-Torres S; Kuhn E; Díaz-Montes T; Parrilla-Castellar E; Lawson FP; Folawiyo O; Ili-Gangas C; Brebi-Mieville P; Eshleman JR; Herman J; Shih IM; Sidransky D; Guerrero-Preston R
    Cancer Prev Res (Phila); 2020 Sep; 13(9):783-794. PubMed ID: 32581010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histotype-specific copy-number alterations in ovarian cancer.
    Huang RY; Chen GB; Matsumura N; Lai HC; Mori S; Li J; Wong MK; Konishi I; Thiery JP; Goh L
    BMC Med Genomics; 2012 Oct; 5():47. PubMed ID: 23078675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.